Advertisement

Topics

Amgen/Novartis potential blockbuster migraine med gets FDA nod

04:35 EDT 18 May 2018 | Pharmafile

The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig is the first CGRP inhibitor to receive approval but won’t be the last, as a number of competitors wait in the wings.

The first-to-market status the drug has achieved allowed Amgen to carefully consider the pricing of the drug in the US market and it has aired on the conservative side.

read more

Original Article: Amgen/Novartis potential blockbuster migraine med gets FDA nod

NEXT ARTICLE

More From BioPortfolio on "Amgen/Novartis potential blockbuster migraine med gets FDA nod"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...